-
Brachytherapy for favorable prognostic prostate cancer in men up to 60 years of age: Long term follow-up Brachytherapy (IF 1.9) Pub Date : 2024-03-12 Juliette Jacques, Nassim Sahki, Émilie Meknaci, Pascal Eschwege, Didier Peiffert, Nicolas Demogeot
Brachytherapy (BT) is a standard treatment for low- and favorable intermediate-risk prostate adenocarcinoma. Few studies have focused on young patients. We therefore evaluated long-term efficacy and toxicity of BT in patients aged ≤ 60 years with low- and favorable intermediate-risk prostate cancer. This retrospective study included patients aged ≤60 years with low- or favorable intermediate-risk prostate
-
Effects of pain management using nonsteroidal anti-inflammatory drug suppositories during brachytherapy for cervical cancer: A single-center prospective observational study Brachytherapy (IF 1.9) Pub Date : 2024-03-10 Yuko Matsuda, Yusuke Nagamine, Tomoya Irie, Takahisa Goto
No standardized pain management protocol exists for intracavitary brachytherapy, and various methods of analgesia have been used in different countries and institutions. This study aimed to investigate the effects of pain management during intracavitary brachytherapy using nonsteroidal anti-inflammatory drugs (NSAIDs) or acetaminophen suppositories. In this single-center, prospective, observational
-
Percutaneous interstitial brachytherapy ablation for targeting oligometastatic gynecologic cancers Brachytherapy (IF 1.9) Pub Date : 2024-03-06 Tiffany S. Lai, Alex Francoeur, Erica Manrriquez, Puja Venkat, Albert Chang, Michael Douek, Simin Bahrami, Steven S. Raman, Sanaz Memarzadeh
Treatment of recurrent oligometastatic gynecologic malignancy may involve targeted surgery, thermal ablation, or CT-guided high-dose-rate interstitial brachytherapy ablation (CT-HDR-IBTA). The purpose of this study was to describe the safety and efficacy of CT-HDR-IBTA for oligometastatic gynecologic malignancies. With institutional review board approval (IRB) approval and compliance with the Health
-
Focal brachytherapy as definitive treatment for localized prostate cancer: A systematic review and meta-analysis Brachytherapy (IF 1.9) Pub Date : 2024-03-02 Osama Mohamad, Luca Nicosia, Etienne Mathier, Elena Riggenbach, Constantinos Zamboglou, Daniel M. Aebersold, Fillipo Alongi, Mohamed Shelan
In this systematic review and meta-analysis, we describe the oncologic and toxicity outcomes of definitive focal brachytherapy for prostate cancer. A PROSPERO registered study (CRD42023410170) was conducted following the Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA) guidelines. PubMed, Embase, and The Cochrane Library were searched for studies between 2000 and 2022. Two
-
Design approach and benefits of the 3D-printed vaginal individualized applicator (VIA) Brachytherapy (IF 1.9) Pub Date : 2024-02-23 Agnes Ewongwo, Thomas Niedermayr, Elizabeth A. Kidd
Interstitial gynecologic brachytherapy necessitates precise needle placement, requiring time and expertise. We aimed to simplify interstitial procedures and facilitate optimal needle distribution with individualized vaginal templates to guide interstitial needles. We developed the 3D-printed vaginal individualized applicator (VIA), a cylindrical template containing individualized internal channels
-
Clinical outcomes in borderline and locally advanced pancreatic cancer with the addition of low-dose-rate brachytherapy to standard of care therapy Brachytherapy (IF 1.9) Pub Date : 2024-02-23 Ross J. Taylor, Gregory J. Matthews, Robert H. Aseltine, Emma C. Fields
Surgical resection remains the only curative therapy for pancreatic cancer. Unfortunately, many patients have borderline or unresectable disease at diagnosis due to proximity of major abdominal vessels. Neoadjuvant chemotherapy and radiation are used to down-stage, however, there is a risk that there will be a positive/close surgical margin. The CivaSheet is a low-dose-rate (LDR) brachytherapy device
-
The impact of a positive COVID-19 test on timeliness of radiation in patients receiving brachytherapy Brachytherapy (IF 1.9) Pub Date : 2024-02-22 Eric Roach, Ryan Hutten, Skyler Johnson, Gita Suneja, Jonathan Tward, Daniel Petereit, David Gaffney
-
Salvage brachytherapy for second ipsilateral breast tumor event: Relating dosimetric analysis to late side effects Brachytherapy (IF 1.9) Pub Date : 2024-02-20 Mohammed Abdul-Latif, Jocelyn Gal, Renaud Schiappa, Yassine Rizzi, Mathieu Gautier, Jean-Michel Hannoun-Levi
-
A practical method of estimating medium-heterogeneity corrected dose without a Monte Carlo calculation in ocular brachytherapy using 125I COMS plaques Brachytherapy (IF 1.9) Pub Date : 2024-02-08 Yongsook C. Lee, Mehran Nik Akhtar, Yongbok Kim, Jae Won Jung
-
Patterns of practice survey for cervical cancer brachytherapy in Morocco Brachytherapy (IF 1.9) Pub Date : 2024-02-03 Tarik Chekrine, Fatima Zahra Bellefkih, Ghita Hatim, Zineb Bouchbika, Nadia Benchakroun, Hassan Jouhadi, Nezha Tawfiq, Souha Sahraoui
This study surveyed radiation oncologists in Morocco to explore current practices and perspectives on brachytherapy for cervix cancer. A 37-question survey was conducted in April 2023 among 165 Moroccan radiation oncologists using Google Forms. Of the 93 respondents, 39% treated over 20 patients in 2022 using 3D image-guided brachytherapy (BT) through the HDR technique; 2D techniques were not reported
-
Impact of the COVID-19 pandemic on brachytherapy and cancer patient outcomes: A systematic review Brachytherapy (IF 1.9) Pub Date : 2024-02-01 Shreel Parikh, Yingting Zhang, Zohaib Sherwani, Ritesh Kumar, Nisha Ohri, Imraan Jan, Irina Vergalasova, Salma Jabbour, Lara Hathout
PURPOSE/OBJECTIVE(s) To assess the impact of the COVID-19 pandemic on the use of brachytherapy in patients with gynecologic and prostate cancers including treatment delays, increased burden of mortality, and associated clinical outcomes. MATERIALS/METHODS A comprehensive search of PubMed, Cochrane Library, CINAHL, Scopus, and Web of Science was conducted using Preferred Reporting Items for Systematic
-
Keeping your best options open with AI-based treatment planning in prostate and cervix brachytherapy Brachytherapy (IF 1.9) Pub Date : 2024-02-01 Leah R.M. Dickhoff, Renzo J. Scholman, Danique L.J. Barten, Ellen M. Kerkhof, Jelmen J. Roorda, Laura A. Velema, Lukas J.A. Stalpers, Bradley R. Pieters, Peter A.N. Bosman, Tanja Alderliesten
Without a clear definition of an optimal treatment plan, no optimization model can be perfect. Therefore, instead of automatically finding a single “optimal” plan, finding multiple, yet different near-optimal plans, can be an insightful approach to support radiation oncologists in finding the plan they are looking for. BRIGHT is a flexible AI-based optimization method for brachytherapy treatment planning
-
Establishing a fingerprinting method for fast catheter identification in HDR brachytherapy in vivo dosimetry Brachytherapy (IF 1.9) Pub Date : 2024-01-28 Daline Tho, Cédric Bélanger, Erik B. Jørgensen, Jérémie Tanguay, Haydee M.L. Rosales, Sam Beddar, Jacob G. Johansen, Gustavo Kertzscher, Marie-Claude Lavallée, Luc Beaulieu
PURPOSE To use quantities measurable during in vivo dosimetry to build unique channel identifiers, that enable detection of brachytherapy errors. MATERIALS AND METHODS Treatment plan of 360 patients with prostate cancer who underwent high-dose-rate brachytherapy (range, 16–25 catheters; mean, 17) were used. A single point virtual dosimeter was placed at multiple positions within the treatment geometry
-
Brachytherapy for rectal and anal cancer: Where are we and current perspectives? Brachytherapy (IF 1.9) Pub Date : 2024-01-25 Alexandra Stewart
Anal and rectal cancers were some of the first disease sites treated with brachytherapy due to the anatomic ease of implantation. As external beam radiotherapy grew in popularity the use of ano-rectal brachytherapy declined. However, the past few years have seen a steady resurgence in the use of brachytherapy in the ano-rectum supported by the use of large clinical series and randomized trials. The
-
Long-term outcomes of salvage transurethral high-dose-rate brachytherapy combined with external beam radiation therapy for anastomotic recurrence of prostate cancer after radical prostatectomy: A retrospective analysis Brachytherapy (IF 1.9) Pub Date : 2024-01-20 Kenta Watanabe, Nobuhiko Kamitani, Naoki Ikeda, Yujiro Kawata, Ryoji Tokiya, Takafumi Hayashi, Yoshiyuki Miyaji, Tsutomu Tamada, Kuniaki Katsui
BACKGROUND High-dose-rate brachytherapy (HDR-BT) delivers high-dose radiation to local lesions within a short treatment period. There are no reports of salvage transurethral HDR-BT for biochemical recurrence (BCR) after radical prostatectomy. Thus, we aimed to evaluate the usefulness of salvage transurethral HDR-BT with external beam radiation therapy (EBRT) for anastomotic prostate cancer recurrence
-
Definitive radiation for advanced cervix cancer is not associated with vaginal shortening—a prospective vaginal length and dose correlation Brachytherapy (IF 1.9) Pub Date : 2024-01-18 Amir Owrangi, Astrid Medrano, Yin Gao, Samaneh Kazemifar, Brian Hrycushko, Paul Medin, Chika Nwachukwu, Xun Jia, Kevin Albuquerque
Purpose Prospectively measure change in vaginal length after definitive chemoradiation (C-EBRT) with Intracavitary Brachytherapy (ICBT) for locally advanced cervix cancer (LACC) and correlate with vaginal dose (VD). Materials and Methods Twenty one female patients with LACC receiving C-EBRT and ICBT underwent serial vaginal length (VL) measurements. An initial measurement was made at the time of the
-
-
-
-
Advanced navigation technology enables endobronchial brachytherapy for peripheral lung cancer: An old technique plays a new role Brachytherapy (IF 1.9) Pub Date : 2023-12-30 Yishi Li, Juan Jiang, Qingfeng Jiang, Wenli Lu, Haixia Cui, Yanbo Song, Wencong Li, Tao Zhang, Longhao Li
PURPOSE To investigate the feasibility of super-selectively endobronchial brachytherapy in the treatment of peripheral lung cancer guided by advanced navigation technology. Methods AND MATERIALS Six patients with peripheral lung tumors successfully underwent treatment with super-selectively endobronchial brachytherapy guided by advanced navigation technology following pathway planning and were subsequently
-
Development and clinical implementation of simple needle attachment post placement interstitial template (SNAPP-IT) enabling a shorter, more direct needle path while preserving tumor visualization Brachytherapy (IF 1.9) Pub Date : 2023-12-29 Claire C. Baniel, Caressa Hui, Pete A. Franco, Thomas Niedermayr, Elizabeth A. Kidd
Purpose Historical gynecologic interstitial brachytherapy templates block direct tumor visualization during needle placement, presenting an opportunity for clinical innovation to develop a novel interstitial template allowing direct tumor visualization during needle insertion. METHODS AND MATERIALS We designed and implemented a novel interstitial template, simple needle attachment post placement interstitial
-
Safety of high-dose rate (HDR) brachytherapy for patients with prostate cancer and history of prior chemoradiation for rectal cancer: A case series Brachytherapy (IF 1.9) Pub Date : 2023-12-29 Horatio Thomas, Jie Jane Chen, Hasan Abdul-Baki, Ali Sabbagh, Haitham Shaheen, Oi Wai Chau, Nauman Malik, Alan Ayoub, Comron Hassanzadeh, I-Chow Hsu, Osama Mohamad
Purpose A history of prior pelvic radiation therapy (RT) for rectal cancer is a relative contraindication for definitive RT for prostate cancer. High-dose-rate (HDR) brachytherapy can significantly limit the dose to surrounding tissues compared to external beam RT. However, there is limited data surrounding its safety in patients with prior pelvic RT. Methods and Materials A retrospective chart review
-
Real-time definition of single seed placement sensitivity in low-dose-rate prostate brachytherapy Brachytherapy (IF 1.9) Pub Date : 2023-12-23 Katharina I. Jerg, Ernest Chukwudi N. Okonkwo, Frank A. Giordano, Yasser Abo-Madyan, Felix Momm, Jürgen W. Hesser
PURPOSE: In low-dose-rate brachytherapy, iodine-125 seeds are implanted based on a treatment plan, generated with respect to different dose constraints. The quality of the dose distribution depends on a precise seed placement, however, during treatment planning the impact on the dose parameters when certain seeds fail to be placed precisely is not clear. METHODS AND MATERIALS: We developed a method
-
Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy Brachytherapy (IF 1.9) Pub Date : 2023-12-20 Gohar S. Manzar, Molly B. El Alam, Erica J. Lynn, Tatiana V. Karpinets, Timothy Harris, David Lo, Kyoko Yoshida-Court, Tatiana Cisneros Napravnik, Julie Sammouri, Daniel Lin, Lauren M. Andring, Julianna Bronk, Xiaogang Wu, Travis T. Sims, Geena Mathew, Kathleen M. Schmeler, Patricia J. Eifel, Anuja Jhingran, Lilie L. Lin, Melissa M. Joyner, Lauren E. Colbert
Background Chemoradiation (CRT) may modulate the immune milieu as an in-situ vaccine. Rapid dose delivery of brachytherapy has unclear impact on T-cell repertoires. HPV-associated cancers express viral oncoproteins E6/E7, which enable tracking antigen/tumor-specific immunity during CRT. Methods Thirteen cervical cancer patients on a multi-institutional prospective protocol from 1/2020–1/2023 underwent
-
Redefining the role of pulsed-dose-rate brachytherapy in cervical cancer treatment using a preplanned approach Brachytherapy (IF 1.9) Pub Date : 2023-12-17 Pierre Annede, Charlotte Robert, Sophie Espenel, Isabelle Dumas, Cyrus Chargari
Introduction This study aims to determine predictive factors for cervical cancer patients who would benefit more from high-dose-rate (HDR) or pulsed-dose-rate (PDR) brachytherapy. Methods The sample included 50 patients treated with brachytherapy following external radiochemotherapy. PDR plans were compared to HDR preplans, with a focus on patients who may benefit from PDR using preplan metrics and
-
A study on short-term efficacy and safety of Iodine-125 brachytherapy coupled with preoperative arterial chemoembolization for hypervascular spinal metastasis Brachytherapy (IF 1.9) Pub Date : 2023-12-02 Menglong Zhang, Menglin Zhang, Miaoshen Yu, Yusheng Song, Yan Wang
PURPOSE Hypervascular spinal metastatic malignancies can cause severe pain and intraoperative bleeding and selection of appropriate treatment can be challenging. This study aimed to observe the short-term efficacy and safety of Iodine-125 brachytherapy (125I BT) combined with preoperative transcatheter arterial chemoembolization (TACE) for hypervascular spinal metastasis. METHODS This study included
-
Safe dose escalation and reduction of the fraction number of uterine cervical brachytherapy using a gel spacer in the rectovaginal and vesicouterine septum: A planning study Brachytherapy (IF 1.9) Pub Date : 2023-11-30 Jun Takatsu, Naoya Murakami, Yoichi Muramoto, Tatsuki Karino, Masaki Oshima, Yasuo Kosugi, Terufumi Kawamoto, Yasuhisa Terao, Naoto Shikama
PURPOSE To evaluate the possibility of dose escalation and reduction of fraction number in cervical brachytherapy using a gel spacer. MATERIAL AND METHODS Twenty patients with uterine cervical cancer treated with image-guided adaptive brachytherapy (IGABT) were selected. Hyaluronic acid gel injection (HGI) was performed in the rectovaginal and vesicouterine septum for 10 patients. The other ten patients
-
Gynecological technical notes for appropriate spacer injections Brachytherapy (IF 1.9) Pub Date : 2023-11-30 Mariko Nakahara, Naoya Murakami, Takahito Chiba, Ayaka Nagao, Kae Okuma, Tairo Kashihara, Tomoya Kaneda, Kana Takahashi, Koji Inaba, Yuko Nakayama, Tomoyasu Kato, Hiroshi Igaki
Background Despite its efficacy, if adherence to dose constraints for surrounding normal tissues proves unattainable, the risk of late radiation-related adverse events after primary radiotherapy involving brachytherapy remains a noteworthy concern. Some studies suggest that similar to prostate radiotherapy, spacers may potentially reduce doses to surrounding healthy rectal or bladder tissues. However
-
Heterogeneous physical phantom for I-125 dose measurements and dose-to-medium determination Brachytherapy (IF 1.9) Pub Date : 2023-11-27 Paula Cristina Guimarães Antunes, Paulo de Tarso Dalledone Siqueira, Julian Marco Barbosa Shorto, Hélio Yoriyaz
PURPOSE In this paper we present a further step in the implementation of a physical phantom designed to generate sets of “true” independent reference data as requested by TG-186, intending to address and mitigate the scarcity of experimental studies on brachytherapy (BT) validation in heterogeneous media. To achieve this, we incorporated well-known heterogeneous materials into the phantom in order
-
Toward a deep learning-based magnetic resonance imaging only workflow for postimplant dosimetry in I-125 seed brachytherapy for prostate cancer Brachytherapy (IF 1.9) Pub Date : 2023-11-25 Johanna Grigo, Andre Karius, Jannis Hanspach, Lion Mücke, Frederik B. Laun, Yixing Huang, Vratislav Strnad, Rainer Fietkau, Christoph Bert, Florian Putz
Background and purpose The current standard imaging-technique for creating postplans in seed prostate brachytherapy is computed tomography (CT), that is associated with additional radiation exposure and poor soft tissue contrast. To establish a magnetic resonance imaging (MRI) only workflow combining improved tissue contrast and high seed detectability, a deep learning-approach for automatic seed segmentation
-
Dosimetric comparison of stereotactic MR-guided radiation therapy (SMART) and HDR brachytherapy boost in cervical cancer Brachytherapy (IF 1.9) Pub Date : 2023-11-23 Neris Dincer, Gamze Ugurluer, Teuta Zoto Mustafayev, Anatolia Serkizyan, Gokhan Aydin, Görkem Güngör, Bulent Yapici, Banu Atalar, Enis Özyar
PURPOSE The standard of care in locally advanced cervical cancer (LACC) is concomitant chemoradiotherapy followed by high-dose-rate brachytherapy (HDR-BT). Although previous studies compared HDR-BT with stereotactic body radiotherapy (SBRT), there is scarce data regarding the dosimetric outcomes of stereotactic MR-guided adaptive radiation therapy (SMART) boost in lieu of HDR-BT. METHODS AND MATERIALS
-
-
-
-
A postimplant dosimetry simulation framework for robustness evaluation in permanent breast seed implant brachytherapy Brachytherapy (IF 1.9) Pub Date : 2023-11-08 Claire Zhang, Jeffrey L. Andrews, Deidre Batchelar, Juanita Crook, Michelle Hilts
BACKGROUND Permanent breast seed implant (PBSI) brachytherapy is a promising treatment that has the potential to be widely utilized with increased standardization, optimization, and robustness. Excellent early efficacy and very high patient acceptance were reported, however, to further evaluate and improve planning strategies, a framework to quantify plan robustness to implant uncertainties is necessary
-
Efficacy of high-dose-rate brachytherapy with different radiation source activities among cervical cancer patients and risk factors for long-term outcomes: A 6-year retrospective study Brachytherapy (IF 1.9) Pub Date : 2023-10-31 Fengyu Wen, Chenguang Li, Baosheng Liang, Jing You, Xiaofan Li, Jingyuan Wang, Hongjia Liu, Fulin Wang, Zhengkun Dong, Yibao Zhang
PURPOSE This study aimed to assess the impact of dose rates due to natural decay of Iridium-192 sources and the risk factors of clinical outcomes for cervical cancer patients treated with high-dose-rate (HDR) brachytherapy. METHODS AND MATERIALS Four ninety-four patients were divided into relatively-high-radioactive (rHR), relatively-medium-radioactive (rMR), and relatively-low-radioactive (rLR) groups
-
Comparing long-term sexual dysfunction across different uterine cancer treatment modalities Brachytherapy (IF 1.9) Pub Date : 2023-10-31 Alison K. Yoder, David S. Lakomy, Juliana Wu, Lauren M. Andring, Kelsey L. Corrigan, Bryan Fellman, Anuja Jhingran, Ann H. Klopp, Lauren E. Colbert, Pamela T. Soliman, Michael M. Frumovitz, Susan K. Peterson, Lilie L. Lin
INTRODUCTION The objective of this study was to assess differences in long-term sexual and menopausal side effects after uterine cancer treatment among treatment modalities. METHODS AND MATERIALS This is a cross-sectional study that examined women treated for uterine cancer from 2006–2018. Eligible women included those who underwent a hysterectomy/bilateral salpino-oophorectemy alone (HS), with brachytherapy
-
Redefining bladder neck dose in low-dose-rate prostate brachytherapy–Can we improve urinary toxicity without impacting disease control? Brachytherapy (IF 1.9) Pub Date : 2023-10-09 Sean A. Koerner, Ronald M. Benoit, Sushil Beriwal, Ryan P. Smith
BACKGROUND We sought to assess the impact of bladder neck dose (BND) on patient reported urinary toxicity, and feasibility of relative urethral sparing technique in prostate brachytherapy (PB). METHODS AND MATERIALS We retrospectively identified bladder neck as a point dose on post-implant CT scans in patients treated with 131Cs PB. Urinary symptoms were assessed through EPIC questionnaires. Patient
-
Outcomes and comparison of dosimetric parameters between intracavitary (Fletcher) and combined intracavitary/interstitial (Utrecht) brachytherapy in locally advanced cervical cancer Brachytherapy (IF 1.9) Pub Date : 2023-10-07 Kashif Ali Sarwar, Sameed Hussain, Abdus Samad Syed, Khurram Khan, Talha Maqsood, Tariq Azeem
OBJECTIVE To report outcomes of combined intracavitary/interstitial (IC/IS) image-guided brachytherapy (IGBT) in locally advanced cervical cancer, and to compare its dosimetric parameters with intracavitary-only (IC) brachytherapy in a first-in-country experience. METHODS AND MATERIALS Between January 2021 and September 2022, a total of 160 insertions were done in 40 patients with FIGO IB3-IVA cervical
-
US-guided EM tracked system for HDR brachytherapy: A first in-men randomized study for whole prostate treatment Brachytherapy (IF 1.9) Pub Date : 2023-10-07 Marie-Claude Lavallee, Audrey Cantin, Sylviane Aubin, Martine Lefebvre, Anne-Sophie Marrier, Isabelle Bouchard, Cedric Fiset, Alexandre Villeneuve-Gauthier, William Foster, Andre-Guy Martin, Damien Carignan, Luc Beaulieu, Eric Vigneault
PURPOSE An electromagnetic tracking device (EMT) has been integrated in an HDR 3D ultrasound guidance system for prostate HDR. The aim of this study was to compare the efficiency of HDR workflows with and without EM tracking. METHODS AND MATERIALS A total of 58 patients with a 15 Gy HDR prostate boost were randomized in two arms and two operation room (OR) procedures using: (1) the EMT investigational
-
Analysis of multicatheter interstitial brachytherapy: Accelerated partial breast irradiation in a retrospective cohort of early-stage breast cancer patients Brachytherapy (IF 1.9) Pub Date : 2023-10-06 Samantha Sigurdson, Stephane Thibodeau, Logan Montgomery, Tim Olding, Wilma Hopman, Martin Korzeniowski
PURPOSE To determine cardiac dose received by patients treated with high dose rate interstitial brachytherapy. Patients with early-stage, node negative breast cancer can be treated using multi-catheter interstitial brachytherapy accelerated partial breast irradiation (MIB-APBI), with the benefit of reduced treatment volumes and favorable toxicity. METHODS AND MATERIALS We conducted a retrospective
-
Image-guided preplanning workflow for high-dose-rate interstitial brachytherapy for gynecological malignancies Brachytherapy (IF 1.9) Pub Date : 2023-09-28 Y. Jessica Huang, Cristina M. DeCesaris, Vikren Sarkar, Hui Zhao, Jeremy Kunz, Geoff Nelson, Xing Li, Gita Suneja, Lindsay M. Burt, David K. Gaffney
Purpose To demonstrate image-guided preplan workflows for high-dose-rate (HDR) brachytherapy for advanced gynecological malignancies. METHODS AND MATERIALS Two different preplanning scenarios are presented: (1) CT- or MRI-based preplan with partial applicator in place; (2) Preplans generated from prior fractions. The first scenario can be applied to Syed-Neblett template-based implants or hybrid brachytherapy
-
Prognostic value of pretreatment FDG PET-CT for short-term efficacy of radioactive iodine-125 seed implantation in patients with NSCLC Brachytherapy (IF 1.9) Pub Date : 2023-09-26 Tianpeng Hu, Jie Shen, Menglin Shao, Xuemin Feng, Dongyan Lu, Enci Ding
PURPOSE To analyze the short-term clinical response of radioactive iodine-125 seed implantation (I125-SI) in patients of non–small-cell lung cancer (NSCLC) and explore possible correlations of various metabolic parameters of pretreatment FDG PET-CT with the short-term efficacy of this treatment modality. METHODS AND MATERIALS The present study is a retrospective analysis of treatment records of 46
-
Viability of focal dose escalation to prostate cancer intraprostatic lesions using HDR prostate brachytherapy Brachytherapy (IF 1.9) Pub Date : 2023-09-23 Joel Poder, Samantha Radvan, Andrew Howie, Farshad Kasraei, Annaleise Parker, Joseph Bucci, Annette Haworth
PURPOSE This study aimed to determine the viability of focal dose escalation to prostate cancer intraprostatic lesions (IPLs) from multiparametric magnetic resonance (mpMRI) and prostate-specific membrane antigen positron emission tomography (PSMA-PET) images using high-dose-rate (HDR) prostate brachytherapy (pBT). METHODS AND MATERIALS Retrospective data from 20 patients treated with HDR pBT was utilized
-
Conformal 3D computed tomography planned endoluminal brachytherapy for the local control of esophageal cancer Brachytherapy (IF 1.9) Pub Date : 2023-09-22 Christopher M. Jones, Annabel Lyles, Peter Bownes, Rebecca Goody, Mohan Hingorani, Eldho Joseph, Ganesh Radhakrishna
Purpose To outline the toxicity, tolerability, and efficacy of a 3D conformal computed tomography planned endoluminal brachytherapy (ELBT) treatment for esophageal adenocarcinoma (OAC) or squamous cell carcinoma (OSCC). Methods and Materials A retrospective single-center analysis of toxicity, tolerability, and outcomes for 65 consecutive patients with OAC/OSCC who received 6–8Gy in one fraction or
-
-
-
-
Comparison of intraluminal brachytherapy combined with and without stent placement for treatment of obstructive jaundice induced by tumor thrombus Brachytherapy (IF 1.9) Pub Date : 2023-09-19 HuiYi Sun, MinJie Yang, FeiHang Wang, DanYang Zhao, XuDong Qu, ZhiPing Yan, FuYou Li, LingXiao Liu
PURPOSE To compare the safety and efficacy of intraluminal brachytherapy with iodine-125 (125I) seed strand implantation combined with and without stent placement to treat patients with obstructive jaundice induced by tumor thrombus. METHODS Between January 2018 and June 2022, 42 patients with malignant obstructive jaundice (MOJ) induced by tumor thrombus were included. 20 patients received 125I seed
-
Surgically targeted radiation therapy (STaRT) for recurrent brain metastases: Initial clinical experience Brachytherapy (IF 1.9) Pub Date : 2023-09-16 Tugce Kutuk, Ranjini Tolakanahalli, Vibha Chaswal, Sreenija Yarlagadda, Roberto Herrera, Haley Appel, Alonso La Rosa, Vivek Mishra, D.Jay J. Wieczorek, Michael W. McDermott, Vitaly Siomin, Minesh P. Mehta, Yazmin Odia, Alonso N. Gutierrez, Rupesh Kotecha
PURPOSE This study evaluates the outcomes of recurrent brain metastasis treated with resection and brachytherapy using a novel Cesium-131 carrier, termed surgically targeted radiation therapy (STaRT), and compares them to the first course of external beam radiotherapy (EBRT). METHODS Consecutive patients who underwent STaRT between August 2020 and June 2022 were included. All patients underwent maximal
-
Utilizing a novel hybrid brachytherapy technique FINITO (Freehand Interstitial Needles in addition to Tandem and Ovoid) for locally advanced cervical cancer Brachytherapy (IF 1.9) Pub Date : 2023-09-16 Yue H. Zhang, Sara Martin, Han Liu, Dorin Todor, James J. Sohn, Bridget Quinn, Louise.E. Francis, Melinda Roach, Emma C. Fields
PURPOSE We aimed to assess the clinical feasibility and advantages of using a novel hybrid brachytherapy technique by placing Freehand Interstitial Needles in addition to the Tandem and Ovoid applicator (FINITO) for the treatment of locally advanced cervical cancer (LAC). METHODS AND MATERIALS A retrospective analysis was performed on two cohorts of patients with LACC treated at our institution: 29
-
Clinical implementation of 3D transvaginal ultrasound for intraoperative guidance of needle implant in template interstitial gynecologic high-dose-rate brachytherapy Brachytherapy (IF 1.9) Pub Date : 2023-09-16 Devin Van Elburg, Tyler Meyer, Kevin Martell, Sarah Quirk, Robyn Banerjee, Tien Phan, Aaron Fenster, Michael Roumeliotis
PURPOSE To demonstrate novel clinical implementation of a 3D transvaginal ultrasound (3DTVUS) system for intraoperative needle insertion guidance in perineal template interstitial gynecologic high-dose-rate brachytherapy and assess its impact on implant quality. METHODS AND MATERIALS Interstitial implants began with preimplant 3DTVUS to visualize the tumor and anatomy, with intermittent 3DTVUS to assess
-
Novel intraocular shielding device for eye plaque brachytherapy using magnetite nanoparticles: A proof-of-concept study using radiochromic film and Monte Carlo simulations Brachytherapy (IF 1.9) Pub Date : 2023-09-15 Courtney C. Oare, James P. Dailey, Bruce Gerbi, Clara Ferreira
PURPOSE Eye plaque brachytherapy is a mainstay treatment for uveal melanomas despite potential toxicities to normal tissues. This work proposes a nanoparticle ferrofluid as a novel intraocular shielding device. With a modified magnetic plaque, the shielding particles are drawn to the tumor surface, attenuating dose beyond the tumor while maintaining prescription dose to the target. METHODS AND MATERIALS
-
Reirradiation with advanced brachytherapy techniques in recurrent GYN cancers Brachytherapy (IF 1.9) Pub Date : 2023-09-15 Umesh Mahantshetty, Sheetal R. Kashid, Gargee Mulye, Lavanya Gurram, Reena Engineer, Supriya Chopra, Jaya Ghosh, Seema Gulia, Sudeep Gupta, Yogesh Ghadi, Dheera A., Satish Kohle, Sudarshan Kadam, Santosh Menon, Kedar Deodhar, Amita Maheshwari, Shylasree TS, Shirley Lewis, Nikhil Kalyani, S.K. Shrivastava
Purpose To evaluate clinical outcomes of recurrent gynaecological cancers treated with reirradiation (reRT) using advanced brachytherapy (BT) technique. Methods and Materials Seventy-six women who underwent reRT with BT for gynaecological cancers at our institute between January 2000 and December 2019 were analysed to determine patient, disease and treatment characteristics and clinical outcomes. Descriptive
-
Uncertainty in magnetic resonance imaging-based prostate postimplant dosimetry: Results of a 10-person human observer study, and comparisons with automatic postimplant dosimetry Brachytherapy (IF 1.9) Pub Date : 2023-09-15 Jeremiah W. Sanders, Chad Tang, Rajat J. Kudchadker, Aradhana M. Venkatesan, Henry Mok, Alexander N. Hanania, Howard D. Thames, Teresa L. Bruno, Christine Starks, Edwin Santiago, Mandy Cunningham, Steven J. Frank
PURPOSE Uncertainties in postimplant quality assessment (QA) for low-dose-rate prostate brachytherapy (LDRPBT) are introduced at two steps: seed localization and contouring. We quantified how interobserver variability (IoV) introduced in both steps impacts dose-volume-histogram (DVH) parameters for MRI-based LDRPBT, and compared it with automatically derived DVH parameters. METHODS AND MATERIALS Twenty-five
-
Improved safety and quality in intravascular brachytherapy: A multi-institutional study using failure modes and effects analysis Brachytherapy (IF 1.9) Pub Date : 2023-09-15 Evan D.H. Gates, Kent Wallner, Jasleen Tiwana, Eric Ford, Mark Phillips, Lan Lu, Vishruta Dumane, Ren-Dih Sheu, Minsun Kim
PURPOSE Highlight safety considerations in intravascular brachytherapy (IVBT) programs, provide relevant quality assurance (QA) and safety measures, and establish their effectiveness. METHODS AND MATERIALS Radiation oncologists, medical physicists, and cardiologists from three institutions performed a failure modes and effects analysis (FMEA) on the radiation delivery portion of IVBT. We identified
-
The American Brachytherapy Society and Indian Brachytherapy Society consensus statement for the establishment of high-dose-rate brachytherapy programs for gynecological malignancies in low- and middle-income countries Brachytherapy (IF 1.9) Pub Date : 2023-09-12 Surbhi Grover, Katie E. Lichter, Anna Likhacheva, Joanne W. Jang, Matthew S. Ning, Tyler P. Robin, William Small, Rajat J. Kudchadker, Jamema Swamidas, Supriya Chopra, Bhavana Rai, Sunil Dutt Sharma, Daya N. Sharma, Thayalan Kuppusamy, Ruijie Yang, Daniel Berger, Lisbeth Cordero Mendez, Scott Glaser, Delnora L. Erickson, Junzo Chino, Umesh Mahantshetty
PURPOSE The global cervical cancer burden is disproportionately high in low- and middle-income countries (LMICs), and outcomes can be governed by the accessibility of appropriate screening and treatment. High-dose-rate (HDR) brachytherapy plays a central role in cervical cancer treatment, improving local control and overall survival. The American Brachytherapy Society (ABS) and Indian Brachytherapy
-
Virtual reality technology: A potential tool to enhance brachytherapy training and delivery Brachytherapy (IF 1.9) Pub Date : 2023-09-09 Arpan V. Prabhu, Melissa Peterman, Anam Kesaria, Santanu Samanta, Richard Crownover, Gary D. Lewis
Abstract not available
-
Actinium-225 Targeted Agents: Where Are We Now? Brachytherapy (IF 1.9) Pub Date : 2023-09-09 Firas Mourtada, Katsumi Tomiyoshi, Jennifer Sims-Mourtada, Yuki Mukai-Sasaki, Takayuki Yagihashi, Yuta Namiki, Taro Murai, David J. Yang, Tomio Inoue
α-particle targeted radionuclide therapy has shown promise for optimal cancer management, an exciting new era for brachytherapy. Alpha-emitting nuclides can have significant advantages over gamma- and beta-emitters due to their high linear energy transfer (LET). While their limited path length results in more specific tumor 0kill with less damage to surrounding normal tissues, their high LET can produce
-
A new way to visualize prostate brachytherapy needles using ultrasound color Doppler and needle surface modifications Brachytherapy (IF 1.9) Pub Date : 2023-08-30 Justine M. Dupere, Eric E. Brost, Susheil Uthamaraj, Christine U. Lee, Matthew W. Urban, Bradley J. Stish, Christopher L. Deufel
PURPOSE Suboptimal ultrasound conspicuity of the brachytherapy applicator can lead to inaccurate image reconstructions of the applicator resulting in decreased tumor control or increased normal tissue dose. This feasibility study aims to improve ultrasound conspicuity of high-dose rate (HDR) brachytherapy needles by modifying the surface of the needles to produce a color Doppler twinkling signature